Last Updated on September 28, 2025 by The Health Master
CDSCO
The regulatory landscape is evolving rapidly, and one of the leaders in this transformation is India’s drug regulatory authority, the Central Drugs Standard Control Organisation (CDSCO).
Following a significant digitization of operations, the CDSCO is on the path to faster, smarter regulation with greater transparency.
It is beyond just de-bureaucratization; it’s a matter of ensuring drug safety and international competitiveness.
Digitization Leap: Statistical Evidence
When 97% of operations are digitized, it’s no wonder the world is going digital.
CDSCO’s transition to almost all online functioning has decreased inefficiency by 25%, according to Dr. Rajeev Singh Raghuvanshi, the current Drugs Controller General of India (DCGI).
This digitization also means that every team member has access to a personalized dashboard to see what files are up on their end and where they are in the turnaround process.
Simple but effective, this advancement fosters accountability and rapid response, which is critical for approvals that may otherwise sit unattended at administrative levels.
- Export Approvals: Export NOCs (No Objection Certificates) took ages to achieve; now, it takes fewer than seven days to secure one digitally. –
- Drug Safety Assurance: By digitizing functions and controlling what goes in and out of the country more stringently, only the approved drugs leave the nation, ensuring safety for all in India and abroad.
Easier Regulations to Help Us All
Of course, technology cannot do it all; therefore, the CDSCO has examined its practices and begun simplifying drug-related regulations to cut unnecessary red tape.
This allows experts to focus on where they are needed most determining whether new drugs meet innovation and safety standards rather than wasting time on superfluous tasks.
“By simplifying regulations operationally, we are paving the way to revisit and revise them to be more flexible and aligned with global healthcare needs,” Dr. Raghuvanshi notes.
The effort toward flexibility also inspires India’s domestic pharmaceutical companies to do better.
For example, revisions to Schedule M notification encourage Indian pharmaceutical companies to adopt stricter WHO-GMP (World Health Organization – Good Manufacturing Practices) compliance; this only increases the desirability of Indian drugs for regulated international markets and strengthens India’s presence as a vendor quality supplier for LMICs (low and middle-income countries), of which more than 90% of quality-assured India medicines are supplied.
International Best Practices for Brand Building
India wants to become a part of the world’s drug inspection team; thus, it’s attempting to align with PIC/S (Pharmaceutical Inspection Co-operation Scheme).
Joining this global cooperative body will require all state-level drug regulators to comply with good and best practices.
Thus, the CDSCO created the State Regulatory Index to gauge state performance for regulatory compliance with an accompanying ranking.
Friendly competition will encourage states to improve systems and collaboration with other states.
Thus far, it’s working; over 17 nations recognize the Indian Pharmacopoeia (IP) as applicable regulations at home and abroad; more than 20 nations have entered Memorandum of Agreements (MoUs) with CDSCO for cooperative efforts.
A Shift from Generics to Innovation
For years, India was recognized as the “pharmacy of the world” for its generic options; now, it has transitioned to its focus on innovation (for biosimilar development, specifically) and simultaneous reliance on a regulatory system as a respectable global player.
Furthermore, India’s endeavors in drug safety perpetuate its acclaim. In this regard, the Pharmacovigilance Programme of India (PvPI) observes any issues that may arise.
The PvPI actively reports adverse drug reactions (ADRs) to the Uppsala Monitoring Centre (UMC), a leading pharmacoepidemiology platform.
Through information sharing with the broader public health community, India’s regulators also gain access to ADR data to make informed decisions within their borders.
Q: What does “digitization of operations” mean for the drug regulators?
It means everything goes from paper-processed systems to fully digitalized efforts. Submissions occur online, and developments are tracked in real-time dashboards, which make processes more efficient and transparent.
Disclaimer: This article contains information obtained from the source mentioned below. Our team made changes in the format to rewrite and present the news or article in a unique format.
New Draft Standards for TB IVD Medical Devices: CDSCO
New Draft Standards for IVD Medical Devices: CDSCO
CDSCO Approval: Panel Nod For Alfuzosin-Tadalafil FDC PMS Study
New Recruitment Rules for Deputy Drugs Controller, CDSCO
5 Northern State SDCs Unite Against Counterfeit Drugs
USFDA issued Form 483 to Biocon with 5 observations
USFDA issued Form 483 to Aurobindo with 8 observations
Drug recall: Unichem recalls Cyclobenzaprine HCL Tablets
Govt. amends Uniform Code for Marketing Medical Devices
Govt to amend Clinical Trials Rules to speed up approvals
NPPA fixed retail price of 42 formulations: August 2025
New Draft Standards for TB IVD Medical Devices: CDSCO
